Abstract 2112P
Background
The WHO (World Health Organization) defines elderly as individuals aged 60 years or older in developing countries. It is known that due to sociodemographic changes such as increased life expectancy, there was an increase in the prevalence of cancer diagnosis in this population subgroup. Associated with the fact that historically these individuals are underrepresented in the main oncological clinical studies, the challenge of a better way of evaluating these patients, who inherently have different physiological characteristics, arises. In this context, the Comprehensive Geriatric Assessment (GGA) is consolidated as an adequate application tool. This study aims to evaluate, based on the domains of the CGA, elderly patients with malignant neoplasm of the digestive tract who will start chemotherapy treatment and associate it with the tolerability of the treatment after 3 months.
Methods
This prospective study included patients with neoplasia of the digestive tract: esophagus, stomach, pancreas, biliary tract, colon and rectum, evaluated at baseline and after 3 months of chemotherapy. Patients aged 60 years or older were selected. The CGA was applied at the beginning of the treatment. Treatment tolerability was defined in this study by toxicity and maintenance or not of the chosen treatment at the end of 3 months. The data were registered in Excel and subsequently imported into IBM-SPSS Statistics version 28 for comparative analysis between groups. This study was approved by the ethics committee (CAAE:30127320.0.0000.5505). All patients signed a Term of Free and Informed Consent before inclusion.
Results
50 patients (median age: 68), colorectal (42%). Stage II: 7 patients, III:18, IV: 25.Correlated with toxicity: IADL (Instrumental Activities of Daily Living) and nutritional status. Dependent for IADL developed more G3 toxicity (p= 0.048) and were unable to continue treatment: the Lawton scale (p=0.020) ;Pfeffer questionnaire (p=0.024).Malnourished developed more G3 toxicity (p=0.003) and suspended/modified treatment (p=0.002).
Conclusions
The evaluation of functionality and nutrition domains were associated with toxicity and maintenance of treatment after 3 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2095P - Cancer rehabilitation program for cancer-related fatigue
Presenter: Aizhan Bekisheva
Session: Poster session 06
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06